CLINICAL_TRIALS
trial_result
· 2011-10-26
Clinical Trial Update: A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus [Phase 2]
Summary
A Phase 2 study of LY2599506, a glucokinase activator, in type 2 diabetes mellitus was terminated, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: TERMINATED | Results posted: 2011-10-26